Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns.
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly's Zepbound and Mounjaro.
Novo Nordisk reports strong Q4 profits but warns of slower growth in 2025
Novo Nordisk (NYSE:NVO) posted a better-than-expected net profit of 28.23 billion Danish kroner ($3.98 billion) in the fourth quarter, beating analyst forecasts. The company's blockbuster Wegovy obesity drug saw sales soar 107% year-on-year to 19.87 billion Danish kroner ($2.76 billion), though this was slightly below expectations.
Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.
Wegovy maker Novo Nordisk says surging growth driving emissions higher
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of blockbuster obesity drug Wegovy.
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025
Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it forecast sales to grow at a slower pace in 2025 than last year.
Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside
Novo Nordisk A/S NVO will report its fourth-quarter earnings on Wednesday. Wall Street expects 86 cents in EPS and $11.40 billion in revenues as the company reports before market hours.
Focus: Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
No plan to prop up global health, Novo Nordisk Foundation says, as Trump freezes US aid
The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded foreign aid, and will continue to focus on its core non-communicable disease agenda, an official told Reuters.
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NVO -1.04%), a pioneer in the field, remains one of the leaders.
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data in December disappointed the market.
